22 citations
,
March 2000 in “Clinical endocrinology” This study found that while ethinyl oestradiol and cyproterone acetate effectively treated hirsutism in 90% of patients, 80% experienced relapse within six months after stopping treatment, suggesting long-term use is necessary.
3 citations
,
January 2025 in “Journal of Cutaneous Medicine and Surgery” Many patients with alopecia areata relapse after stopping tofacitinib.
3 citations
,
March 2024 in “Journal of Dermatological Treatment” Baricitinib can lead to hair regrowth in alopecia areata but may also cause relapses.
2 citations
,
July 2024 in “Indian Journal of Dermatology” This study found that a high proportion of alopecia areata patients experienced a relapse, typically within one year, with more extensive initial scalp involvement predicting an earlier return of the disease.
August 2026 in “Journal of the American Academy of Dermatology” This abstract does not report results but indicates that the supplementary material includes comprehensive methodology, additional results, statistical analyses, discussion, and limitations of the Alopecia Areata Relapse Study Group's findings as presented in the main manuscript.
November 2025 in “Frontiers in Medicine” In this prospective cohort, baseline severity, disease activity, and relapse history were identified as key factors influencing response and recurrence in alopecia areata, suggesting that implementing standardized assessments could enhance risk stratification and personalized care approaches.
June 2020 in “Journal of skin and stem cell” This case report describes a 19-year-old female with recurrent alopecia totalis who experienced complete remission after re-treatment with various therapies, emphasizing the importance of long-term follow-up in managing alopecia areata.
18 citations
,
November 2018 in “Annals of the Academy of Medicine Singapore” Sulfasalazine can cause severe allergic reactions leading to long-term autoimmune issues like hair loss and skin discoloration.
13 citations
,
July 2003 in “Annals of the Rheumatic Diseases” This case report describes a 13-year-old girl with various autoimmune symptoms successfully treated with the antibiotic and immunomodulatory drug co-trimoxazole; its potential role in autoimmune disease treatment is explored.
2 citations
,
January 2010 in “Case Reports in Medicine” This case report and literature review explore a potential immunological link between alopecia areata and relapsing polychondritis, suggesting that the latter might be a systemic manifestation of the former.
1 citations
,
October 2018 in “The American journal of gastroenterology” This case report describes a 29-year-old male with relapsing hepatitis A, a rare complication of acute hepatitis A virus infection, characterized by prolonged elevated liver chemistries and persistent HAV IgM, managed conservatively.
April 2016 in “Journal of The American Academy of Dermatology” Dutasteride is more effective than finasteride for hair growth with similar side effects.
2 citations
,
October 2022 in “British journal of haematology” This study reports the first successful use of zanubrutinib to treat a 15-year-old Chinese girl with severe refractory Evans' syndrome, resulting in a sustained recovery of platelet counts and haemoglobin levels.
29 citations
,
January 2016 in “CNS drugs” This review of teriflunomide for relapsing-remitting multiple sclerosis examines its clinical and safety outcomes, finding it significantly reduces relapse rates and disability progression while being generally well-tolerated.
6 citations
,
November 1996 in “Archives of Dermatology” This case report describes a 29-year-old Japanese-Paraguayan man who experienced a relapse of leprosy 14 years after initial treatment, presenting with severe pain and skin lesions but no sensory impairment.
5 citations
,
July 2018 in “Pediatrics” This case report describes a previously healthy 3-year-old girl who developed scurvy symptoms not directly linked to vitamin C dietary deficiency, highlighting the potential for misdiagnosis in similar cases.
January 2024 in “Indian Journal of Paediatric Dermatology” In this case report, the authors describe a rare association of alopecia universalis with frequently relapsing nephrotic syndrome in a 3-year-old girl, suggesting a possible genetic and immune-related cause, and note that tofacitinib treatment was ineffective in her case.
39 citations
,
November 2015 in “Pediatric Nephrology” In this study, rituximab treatment for children with steroid-dependent nephrotic syndrome was associated with a longer remission time and fewer side effects compared to cyclophosphamide.
22 citations
,
November 2002 in “Clinical journal of oncology nursing” This article discusses arsenic trioxide as a treatment for refractory or relapsed acute promyelocytic leukemia, noting its effectiveness and manageable side effects.
16 citations
,
April 2014 in “Expert Opinion on Pharmacotherapy” This review discusses the pharmacological profile of teriflunomide for treating relapsing multiple sclerosis, highlighting its safety and effectiveness in reducing relapses and slowing disability progression, though direct comparisons with other oral medications are lacking.
12 citations
,
December 2002 in “Archives of Dermatology” This case report describes a 49-year-old woman with Sweet syndrome who experienced complete resolution of skin lesions after a prednisone treatment regimen.
9 citations
,
April 2023 in “Experimental Dermatology” This study found that adding allergen immunotherapy to conventional treatment may reduce relapse-related hair loss in house dust mite-allergic alopecia areata patients over a 3-year period.
November 2025 in “Indian Journal of Nephrology” In this case study, a 43-year-old male with anti-GBM disease experienced a relapse triggered by hair dye, leading to diffuse alveolar hemorrhage; managing this with plasmapheresis, intravenous immunoglobulins, and rituximab suggests rituximab may be beneficial for relapsing cases.
July 2025 in “Journal of Cosmetic Dermatology” In this study, authors present a case where a 26-year-old patient with alopecia areata experienced relapse after initially responding to Tofacitinib, mitigated by corticosteroids, highlighting challenges and potential insights into the treatment and pathogenesis of the condition.
In this study, Norwegian researchers followed over 350 patients with porphyria cutanea tarda for an average of 7 years and found that 25% experienced biochemical relapse, suggesting the importance of routine follow-up for early detection and management.
105 citations
,
October 2018 in “Nature” This study found that vismodegib promotes Basal cell carcinoma regression by inducing tumor differentiation but leaves a small population of quiescent cells that can drive relapse, which can be eliminated by adding a Wnt signaling inhibitor.
40 citations
,
April 2013 in “Dermato-endocrinology” In this study, researchers observed vitamin D insufficiency in many patients with Alopecia Areata, suggesting its potential role in managing this autoimmune condition.
39 citations
,
September 2015 in “Clinical Therapeutics” This review summarizes updated US prescribing information for teriflunomide in relapsing multiple sclerosis, highlighting its efficacy in reducing lesion activity and relapse rates but noting potential adverse effects such as headache and diarrhea.
4 citations
,
May 2018 in “Journal of Neuro-Ophthalmology” This review describes the evolution of treatments for relapsing multiple sclerosis, highlighting that while newer potent monoclonal agents can potentially achieve disease remission, they also pose moderate to severe adverse event risks that healthcare providers must understand.
May 2025 in “Frontiers in Immunology” This paper discusses the balance between target tissue destruction and recovery rates in autoimmune diseases, proposing that high recovery rates are crucial for remitting-relapsing patterns, while exercise might not be neuroprotective in secondary progressive multiple sclerosis.